Journal Article

<i>In vitro</i> activity of terbinafine against medically important non-dermatophyte species of filamentous fungi

Guillermo Garcia-Effron, Alicia Gomez-Lopez, Emilia Mellado, Araceli Monzon, Juan L. Rodriguez-Tudela and Manuel Cuenca-Estrella

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 53, issue 6, pages 1086-1089
Published in print June 2004 | ISSN: 0305-7453
Published online June 2004 | e-ISSN: 1460-2091 | DOI: https://dx.doi.org/10.1093/jac/dkh228
In vitro activity of terbinafine against medically important  non-dermatophyte species of filamentous fungi

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care

GO

Show Summary Details

Preview

Objectives: The activity in vitro of terbinafine against 442 clinical isolates of several species of filamentous fungi was analysed.

Methods: A broth microdilution test was carried out following the National Committee for Clinical Laboratory Standards reference method, with modifications described previously.

Results: The geometric mean (GM) of MICs of terbinafine for non-Aspergillus fumigatus species was 0.24 mg/L whereas the GM for A. fumigatus rose as far as 2.92 mg/L. Terbinafine showed a very strong activity in vitro against Penicillium spp., Paecilomyces spp., Trichoderma spp., Acremonium spp. and Arthrographis spp. with GMs <1 mg/L. However, some species such as Scedosporium spp., Fusarium spp., Scopulariopsis brevicaulis, and most of Mucorales exhibited high MICs of the allylamine with GMs ≥ 4 mg/L.

Conclusions: Overall, the GM of MICs of terbinafine was 1.57 mg/L, but significant differences in susceptibilities were seen between genera and species.

Keywords: Keywords: Aspergillus spp., Spanish filamentous fungi, allylamines, antifungals

Journal Article.  2352 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.